Lung Cancer
News
Survival benefit with nivolumab extends to 5 years in NSCLC
Early response portends durable outcome, but the optimal duration of treatment is uncertain.
Article
Leveraging the microbiome to enhance cancer treatment
Dr. Alan Lyss reviews research suggesting that an antibiotic can improve the efficacy of radiotherapy.
Conference Coverage
Personalized cancer vaccine shows early promise across tumor types
The vaccine consists of patient-specific synthetic neoantigen peptides and is given to patients in the adjuvant setting.
News
Rankings of most common cancers to shift over next 20 years
“It’s time to shift focus to some of the less commonly diagnosed cancers with the lowest survival rates, like pancreatic and liver cancer.”
News
Increased cancer risk from night shift due to gene dysregulation?
A simulated night shift schedule significantly altered the normal circadian rhythmicity of genes.
Article
Cancer screening stopped by pandemic: Repercussions to come?
Conference Coverage
Camrelizumab ‘another brick in the wall’ against squamous NSCLC
Adding camrelizumab to chemotherapy improved survival in patients with squamous non–small cell lung cancer.
Conference Coverage
Can benefits of SBRT outweigh risks in ultra-central lung tumors?
Stereotactic body radiotherapy for ultra-central lung tumors offers good disease control and survival but carries a risk of lung hemorrhage.
News
Melatonin not recommended for early-stage NSCLC
There was a hint of benefit with melatonin among patients with stage III/IV NSCLC.
News
FDA scrutinizes cancer therapies granted accelerated approval
